Laboratoires Servier
Laboratoires Servier, a prominent French pharmaceutical company, is headquartered in Suresnes, France. Founded in 1954, Servier has established itself as a key player in the global healthcare industry, with a strong presence in Europe, Asia, and Africa. The company focuses on innovative treatments in various therapeutic areas, including cardiology, diabetes, oncology, and neurology. Servier is renowned for its commitment to research and development, investing significantly in new drug discovery and development. Its core products, such as the antihypertensive medication Perindopril, exemplify the company's dedication to improving patient outcomes through unique formulations and comprehensive treatment solutions. With a robust portfolio and a reputation for quality, Laboratoires Servier continues to strengthen its market position, achieving notable milestones in both innovation and patient care.
DitchCarbon Score
How does Laboratoires Servier's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Laboratoires Servier's score of 39 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Laboratoires Servier's reported carbon emissions
In 2023, Laboratoires Servier reported total greenhouse gas emissions of approximately 102,991,000 kg CO2e, comprising 69,691,000 kg CO2e from Scope 1 and 33,300,000 kg CO2e from Scope 2. The company has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 emissions by 25% by 2030, using 2016 as the baseline year. Additionally, Servier plans to cut Scope 3 emissions from capital goods, waste generated in operations, business travel, and employee commuting by 25%, and from downstream transportation and distribution by 21%, all by 2030 from the same base year. Furthermore, Servier is working with key suppliers, representing 52% of emissions from purchased goods and services, to establish science-based targets for Scope 1 and 2 emissions by 2024. These initiatives align with industry standards for climate action and demonstrate Servier's commitment to reducing its carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2016 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 62,044,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 54,578,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | - | - | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Laboratoires Servier is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
